- Home
- Sitemap
Sitemap
Main Menu
- Home
- Technologies
- Products
- Services
- Company
- News
- Press Releases
- SomaGenics' sshRNA Technology Demonstrates Efficacy of RNAi Againt Hepatitis C Virus
- SomaGenics Reports Study on Mechanism of Action of Its Therapeutic Platform
- SomaGenics Announces Issue of Key Patent for Its sshRNA Technology and Receipt of Two New Small Business Innovation NIH Grants
- Exploiting miRNA’s Potential for Diagnostics and Drugs
- SomaGenics Reports on successful HCV virus inhibition with its therapeutic sshRNA.
- SomaGenics demonstrates that their short synthetic shRNAs function as a direct-acting anti-viral agent against Hepatitis C
- SomaGenics Awarded Four Patents Spanning Its miRNA and RNAi Programs
- SomaGenics Receives $2,275,000 in NIH Funding to Develop its RNAi Therapeutics and microRNA Technologies
- Three SomaGenics Publications Demonstrate Successful Inhibition of the Hepatitis C Virus by Therapeutic sshRNA™ and Confirm Mechanism of Action
- Somagenics Awarded 2-Year NIH grant to develop NGS microRNA Library Technology
- SomaGenics launches miR-ID® platform for highly sensitive and specific quantification of microRNAs (miRNAs)
- SomaGenics Awarded Second NIH Grant to Develop resQ-RNA™ Technology to Quantify Fragmented mRNA From Degraded Samples
- SomaGenics Presents Progress in Diabetic Wound Healing at the 10th RNA Consortium Meeting
- Rubicon Genomics Licenses Commercialization Rights from SomaGenics for Its RealSeq®-AC Technology for High-Throughput Sequencing of Small RNAs
- SomaGenics to present at the 7th non-coding RNA & RNAi Therapeutics conference, Boston, MA on September 14, 2016
- SomaGenics to present at the 12th annual Oligonucleotide Therapeutics Society (OTS) meeting
- SomaGenics secures $1.8M in funding from NIH to further develop the Real-Seq® technology platform
- SomaGenics Granted New Patents for RNA Detection and RNA-based Therapeutics Technologies
- SomaGenics presented research progress at the Symposium on Advanced Wound Care and Wound Healing Society
- SomaGenics Presents RNAi Therapeutic Program
- SomaGenics awarded NIH funding to develop novel cell-free-DNA liquid biopsy platform
- SomaGenics awarded NIH funding to develop NGS Single-Cell analysis of small RNAs
- SomaGenics receives award or allowance of four patents covering its small RNA analysis and therapeutics
- SomaGenics awarded NIH Phase II funding for Targeted NGS of cell-free small RNAs
- SomaGenics Announces Upcoming Data Presentations of its Wound Healing Therapeutic Program
- SomaGenics launches its RealSeq®-biofluids kit and advances liquid biopsy development with new NIH funding for cf-miRNA NGS technology
- Publications
- Press Releases
- Contact
Hidden Menu
- Background sshRNA Technology
- miR-Direct™
- miR-ID® microRNA Detection Platform
- Search SomaGenics.com
- Contact Form
- miR-ID® Kit Order Form
- miR-ID® Kits
- Component Order Form
- miR-ID® Order Form
- Terms of Sale
- miR-ID® Order Form
- Component Ordering Form
- RealSeq®-AC
- RealSeq®-AC Kits
- RealSeq®-AC Order Form
- RealSeq-biofluids Order Form